### **Overview** Bilcare Limited is a leading Indian company specializing in **innovative pharmaceutical packaging solutions** and **end-to-end clinical trial supply services**. With over three decades of operations since its inception in 1987, the company has evolved into a globally recognized partner for pharmaceutical firms and contract research organizations (CROs). It operates through two core business segments: **Pharma Packaging Innovations (PPI)** and **Global Clinical Supplies (GCS)**. The company emphasizes innovation, regulatory compliance, sustainability, and patient-centric design. A major strategic shift since 2023 has repositioned Bilcare to focus on high-growth global businesses, particularly clinical trial services, while streamlining its packaging operations under a subsidiary. --- ### **Strategic Restructuring & Business Focus (2023–2024)** - **Transfer of PPI Business**: In September 2023, Bilcare transferred its **Pharma Packaging Innovations (PPI)** division—including product lines, manufacturing processes, quality systems, and the "Bilcare" brand—to its subsidiary **Caprihans India Limited (CIL)** via a slump sale at fair value. - **Debt-Free & Leaner Structure**: This restructuring made Bilcare Ltd. **debt-free**, reduced overhead costs, and allowed it to refocus on **clinical trial supply chain services** and other high-potential global businesses. - **Continuity of Brand & Operations**: Caprihans continues to manufacture and market pharmaceutical packaging under the **Bilcare brand**, maintaining legacy quality standards and customer trust. - **Ownership**: Caprihans India Limited is 51% owned by the Bilcare Group, with 49% held by external investors. --- ### **Pharmaceutical Packaging Innovations (PPI)** Although now operated by Caprihans, the PPI legacy remains a cornerstone of Bilcare’s reputation for innovation and quality. #### **Core Capabilities (as of Sep 2025)** - **Dominant Materials**: PVC and PVDC films continue to be widely used for solid oral dosage packaging due to their **proven barrier properties and cost efficiency**. - **Next-Gen Sustainable Alternatives**: Adoption of **PET/PE-based laminates** and proprietary coatings is growing, driven by sustainability goals. - **Innovative Products**: - **Venus Elite™**: A **vinyl-free, compact blister packaging** solution offering: - 30–60% space savings vs. strip packaging - Enhanced barrier protection for ultrasensitive drugs - Embedded image-based printing for brand communication - Compatibility with child-resistant/senior-friendly (CRSF) designs - **Bilcare Protect™**: Advanced **anti-counterfeit solutions** with overt and covert security features, already adopted by top-selling brands. - **Optra™**: Environmentally friendly PVC alternative that **eliminates dioxin emissions** during disposal. - **Zeon Aqua**: A **drug-contact material** under global evaluation, recognized for high performance in sensitive formulations. - **Technology & R&D**: - Water-based heat seal lacquers (e.g., 4–5 g/m² formulations), enabling higher production efficiency. - High-speed 6-color gravure printing with auto-registration and online monitoring. - Auto defect detection, GSM measurement, and process optimization. - Multiple **patents filed and granted** (4 new patents in FY22 alone). #### **Market Reach (as of 2023)** - Products registered and approved in **U.S., Europe**, and other major markets. - Exports account for **over 30% of turnover**. - Growing presence in **MENA, South America, Southeast Asia, and Europe**. --- ### **Global Clinical Supplies (GCS) – Core Growth Engine** Bilcare GCS has emerged as a **strategic platform** for global clinical trial logistics and supply chain management. #### **End-to-End IMP Services (as of Sep 2025)** Bilcare provides comprehensive **Investigational Medicinal Product (IMP)** services: - Comparator drug procurement - Pre-formulation R&D and development - Primary and secondary packaging - Temperature-controlled storage (ambient, 2–8°C, -20°C) - Global logistics and distribution - Returns, destruction, and reconciliation - IVRS/IWRS (Interactive Web Response System) - Analytical and regulatory support - Qualified Person (QP) release for EU exports #### **Global Depot Network Expansion** - **Worldwide Coverage**: Bilcare has expanded its **global depot partnerships** to **cover most key regions**, enabling seamless storage, distribution, returns, and destruction. - Supports multinational clinical trials with regional compliance, cold chain integrity, and audit readiness. - Expanded services into **nutraceuticals and medical devices** (e.g., rapid test kits, VTM tubes, RT-PCR, RNA extraction kits). #### **Market Position & Growth Drivers** - The **global comparator sourcing market has doubled in size over the past three years**, driven by rising oncology pipeline activity and demand for transparent, compliant sourcing. - Bilcare is establishing itself as a **major player** due to: - **Quality certifications** (e.g., GDP, GMP) - **QP release capabilities** - Localized sourcing networks - Regulatory audit support (e.g., USFDA, DCGI) - Played critical role in **Covid-19 clinical trials** (2020–2021), providing fast-tracked supplies domestically and internationally. #### **Regulatory & Compliance Strength** - Successfully supports clients during **USFDA audits** and **investigator meetings**. - Passed major customer audits **without critical observations**, reinforcing credibility in highly regulated markets. - Obtained **fast-track approvals** from **DCGI and ICMR** for diagnostic kits during the pandemic. - Facilities and processes aligned with **GDP, GMP, and ICH guidelines**. --- ### **Global Presence & Subsidiaries** - **Bilcare Inc. (USA)**: Wholly owned subsidiary established under Bilcare Mauritius Ltd., supporting North American clinical and packaging operations. - **Bilcare Technologies Singapore Pte. Ltd.** and **Bilcare Technologies Italia Srl**: 100%-owned subsidiaries enhancing global footprint and technical collaboration. - **Caprihans India Limited**: Associated company (51% group ownership), responsible for PPI manufacturing. - **CIL (Caprihans India Ltd.)**: Reported stable financials in FY22 (Revenue: ₹392.89 Cr, EBITDA: ₹26.81 Cr), with decades-long presence in pharma packaging. --- ### **Sustainability & Innovation Focus** Bilcare continues to lead in eco-conscious packaging innovation: - **Vinyl-free solutions** (Venus Elite, Optra) - **Nitrocellulose-free inks, varnishes, and heat seal lacquers** - **Water-based coating technologies** reducing VOC emissions - **Compact packaging** reducing material use and logistics footprint - **Polyolefin-based laminates** for liquids and sensitive formulations - **ARMALAR™**: Extra-high barrier composite for unstable APIs --- ### **Financial & Ownership Highlights** - **Foreign Investment**: ₹80.50 crores as of March 31, 2023. - **Debt Reduction**: Over ₹2,000 crores reduced (~75%) after divestment of non-core overseas units (e.g., credit card and FMCG films) in 2020. - Strong capital structure post-restructuring, enabling focused investment in GCS expansion.